14 completed, 12 unknown, 3 terminated, 2 withdrawn. 17 Phase 2, 11 Phase 1, 7 Phase 3, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Unknown 9, Completed 5, Terminated 2, Withdrawn 1 |
| Phase 1 | 11 | Completed 7, Unknown 4 |
| Phase 3 | 7 | Completed 4, Terminated 1, Unknown 1, Withdrawn 1 |
| Early Phase 1 | 1 | Terminated 1 |
Follow Genta Incorporated: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer Tesetaxel, Capecitabine - Locally Advanced Non-resectable Breast Cancer, Metastatic Breast Cancer | Phase 2 | Unknown | Genta Incorporated | 213 | 2012-05-01 | 2012-06-01 |
| Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer Tesetaxel, Placebo, Capecitabine - Gastric Carcinoma | Phase 2 | Unknown | Genta Incorporated | 580 | 2012-04-01 | 2012-07-24 |
| Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer Tesetaxel-capecitabine-cisplatin - Gastric Carcinoma | Phase 1 / Phase 2 | Unknown | Genta Incorporated | 63 | 2011-05-01 | 2012-03-13 |
| Study of Tesetaxel in Japanese Patients With Solid Tumors Tesetaxel - Advanced Solid Tumors | Phase 1 | Unknown | Genta Incorporated | 12 | 2011-04-01 | 2012-03-13 |
| A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors Tesetaxel plus capecitabine - Solid Tumor | Phase 1 | Unknown | Genta Incorporated | 9 | 2011-03-01 | 2012-07-24 |
| Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer Tesetaxel - Prostate Cancer | Phase 2 | Unknown | Genta Incorporated | 57 | 2011-02-01 | 2012-07-24 |
| Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma Genasense, Paclitaxel, Carboplatin - Melanoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 7 | 2010-12-01 | 2016-02-11 |
| Tesetaxel as First-line Therapy for Metastatic Breast Cancer Tesetaxel once every 3 weeks, Tesetaxel once weekly - Breast Neoplasm | Phase 2 | Unknown | Genta Incorporated | 81 | 2010-11-01 | 2012-07-24 |
| Tesetaxel for Previously Treated Patients With Bladder Cancer Tesetaxel - Carcinoma, Transitional Cell | Phase 2 | Unknown | Genta Incorporated | 33 | 2010-09-01 | 2012-07-11 |
| Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg Capsules Tesetaxel 10 mg with and then without food, Tesetaxel 10 mg without and then with food - Solid Tumors | Phase 1 | Completed | Genta Incorporated | 12 | 2010-06-01 | 2012-07-24 |
| Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer Tesetaxel - Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction | Phase 2 | Unknown | Genta Incorporated | 27 | 2010-03-01 | 2012-03-15 |
| Phase II Study of Tesetaxel in Metastatic Melanoma Tesetaxel - Advanced Melanoma, Cancer | Phase 2 | Completed | M.D. Anderson Cancer Center | 17 | 2010-02-01 | 2018-07-17 |
| Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH Tesetaxel - Melanoma | Phase 2 | Unknown | Genta Incorporated | 27 | 2010-02-01 | 2011-11-08 |
| Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma oblimersen sodium, rituximab, cyclophosphamide - Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma | Early Phase 1 | Terminated | University of Nebraska | 37 | 2008-07-23 | 2023-10-24 |
| Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma RICE, GaRD Treatment - Diffuse Large B-cell Lymphoma | Phase 2 | Withdrawn | Loyola University | 2008-07-01 | 2016-03-16 | |
| Trial of Dacarbazine With or Without Genasense in Advanced Melanoma dacarbazine plus Genasense, dacarbazine plus placebo - Melanoma | Phase 3 | Completed | Genta Incorporated | 300 | 2007-07-01 | 2011-11-07 |
| Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors Oblimersen (Genasense) - Solid Tumors | Phase 1 | Completed | Genta Incorporated | 25 | 2007-05-01 | 2012-04-06 |
| Abraxane and Temodar Plus Genasense in Advanced Melanoma Genasense® (oblimersen), Abraxane® (paclitaxel protein-bound particles for injectable suspension), Temodar® (temozolomide) - Melanoma | Phase 1 | Unknown | Genta Incorporated | 28 | 2006-11-01 | 2011-11-07 |
| This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL) Genasense® (, oblimersen sodium G3139) - Lymphocytic Leukemia | Phase 3 | Withdrawn | Genta Incorporated | 2006-06-01 | 2008-02-11 | |
| Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function Genasense (oblimersen, G3139) - Normal Renal Function, Mildly Impaired Renal Function | Phase 1 | Completed | Genta Incorporated | 23 | 2006-05-01 | 2012-03-13 |
Showing 20 of 31. Sign in to see all of them.
Melanoma (6) · Leukemia (4) · Neoplasms (4) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Breast Neoplasms (2) · Bronchiolitis Obliterans Syndrome (2) · Lymphoma, Large B-Cell, Diffuse (2) · Stomach Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Leukemia, Lymphoid (1) · Leukemia, Myeloid, Acute (1) · Lung Neoplasms (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1)
oblimersen (16) · tesetaxel (12) · Capecitabine (4) · Dacarbazine (3) · Cyclophosphamide (2) · Albumin-Bound Paclitaxel (1) · Biopsy (1) · Carboplatin (1) · Cisplatin (1) · Cytogenetic Analysis (1) · Dexamethasone (1) · Docetaxel (1) · Doxorubicin (1) · Filgrastim (1) · Food (1)
United States (26) · Canada (2) · Germany (2) · Italy (2) · South Korea (2) · Australia (1) · Austria (1) · Czechia (1) · France (1) · Japan (1) · Poland (1) · Russia (1) · Spain (1) · Switzerland (1) · Taiwan (1)
Stanley R. Frankel, MD (4) · Andrew D Seidman, MD (2) · Jaffer Ajani, MD (2) · Agop Y Bedikian, MD (1) · Agop Y. Bedikian, MD, BS (1) · Anna C Pavlick, MD (1) · Dean F Bajorin, MD (1) · Deborah Braccia (1) · Harry Alcorn, PharmD (1) · Harry W Alcorn, PharmD (1) · Julie M Vose, MD MBA (1) · Lee S Schwartzberg, MD, FACP (1) · Michael J Morris, MD (1) · Sapna P. Patel, MD (1) · Scott Smith, MD, PhD, FACP (1)
PMID 16186597, PMID 16730060, PMID 17296974, PMID 19373653, PMID 19738118
P30CA036727 (1)